A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Trial Profile

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs BGB 3111 (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors BeiGene
  • Most Recent Events

    • 16 Jun 2017 According to a BeiGene media release, this trial is intended to support approval of BGB-3111 in China.
    • 09 Mar 2017 According to a BeiGene media release, Professor Jianyong Li of the Jiangsu Province Hospital (the first Affiliated Hospital with Nanjing Medical University) is the lead principal investigator of the trial and first patient has been dosed in this study.
    • 09 Mar 2017 Status changed from planning to recruiting, according to BeiGene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top